[Clinical evaluation of biological response modifiers (BRMs) combined with radiotherapy].
The present status of clinical application and future prospect of immunotherapy using BRMs, especially PS-K, for cancer patients treated by irradiation were described here. Prolonged survivals were revealed in the radiation therapy of patients with carcinoma of lung and uterine cervix concomitant use of PS-K. And the condition necessary for long-term survival with BRMs were thought to be that the tumor was almost disappeared by irradiation. But, there is not an evaluation criteria for BRMs without any direct effects on tumor. Then judgment of clinical usefulness of immunopotentiators are difficult and needs to make new evaluation criteria.
Mitsuhashi
N
N
Dept. of Radiology, Gunma Univ. School of Med.
Okazaki
A
A
Kawashima
M
M
Niibe
H
H
D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy / Q000628:therapy; D009369:Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000628:therapy; D011379:Prognosis; D011509:Proteoglycans / Q000627:therapeutic use*; D011879:Radiotherapy Dosage
D011509:Proteoglycans; C010770:polysaccharide-K